Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which sedative is safer during ERCP? a Head-to-Head trial

NCT ID NCT07702240

Symptom relief Sponsor: Ren Da Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This trial tests two drug combinations used to sedate people during a procedure called ERCP, which examines bile ducts. One group receives esketamine plus propofol, the other sufentanil plus propofol. Researchers track oxygen levels and blood pressure to see which approach causes fewer breathing or blood pressure problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
esketamine and sufentanil, each combined with propofol
What this could lead to
If esketamine proves safer, it could become a preferred sedative for ERCP, reducing breathing and blood pressure complications.
What could go wrong
This is a single-center trial, and results may not apply to all hospitals or patient groups. Both drugs have known side effects like nausea or dizziness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 530 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years * Patients scheduled to undergo endoscopic retrograde cholangiopancreatography (ERCP) * American Society of Anesthesiologists (ASA) physical status I-III * Body mass index (BMI) between 18.5 and 30 kg/m² * Patients requiring sedation for ERCP * Ability to provide written informed consent voluntarily Exclusion Criteria: * Allergy or contraindication to propofol, esketamine, sufentanil, or related medications * Severe hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg) * Severe dysfunction of the heart, lungs, liver, or kidneys * History of central nervous system disorders or psychiatric disorders * Anticipated difficult airway * History of psychiatric disorders or contraindications to ketamine use * Inability to communicate or provide informed consent * Requirement for general anesthesia with endotracheal intubation or intraoperative conversion to general anesthesia with intubation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biliary tract diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia biliary tract disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biliary tract diseases Procedural sedation and analgesia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.